Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript
Ardelyx, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.13. Ardelyx, Inc.
Source: insidermonkey.com
Ryan Deschner News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ryan Deschner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ryan Deschner Today - Breaking & Trending Today
Analyst Highlights 'Rock Solid' Data For Vera Therapeutics' Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy - Vera Therapeutics (NASDAQ:VERA)
72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile.
Source: benzinga.com
What's Going On With Vera Therapeutics Stock Today? - Vera Therapeutics (NASDAQ:VERA)
Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals.
Source: benzinga.com
Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst - Vera Therapeutics (NASDAQ:VERA)
Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion protein currently in a Phase 3 study in IgA Nephropathy (IgAN).
Source: benzinga.com
Patient Demand Drives Ardelyx's Constipation Drug Success Amid IBS-C Treatment Gap, Says Analyst - Ardelyx (NASDAQ:ARDX)
Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing:
Source: benzinga.com